INTRODUCTION
Shigellosis is an infectious disease of global importance, and also an important cause of traveler's diarrhea (1) . Although improved public health measures have greatly reduced its incidence in the developed countries where the disease is now sporadic, it continues to be a major cause of childhood morbidity, deaths and growth-faltering in the developing world where epidemic form of the disease is associated with increased morbidity and deaths (1) (2) (3) (4) (5) .
S. dysenteriae, S. flexneri, S. boydii and S. sonnei are the four species of Shigella which together have over 45 serotypes. S. dysenteriae type 1, the epidemic serotype in the developing countries, causes the most severe form of the disease as well as more complications, and is also the most efficient in acquiring antimicrobial resistance (1, 6, 7) . S. flexneri, endemic in many developing countries, causes a disease of intermediate severity, and S. sonnei, prevalent in the developed countries, generally causes a milder, non-dysenteric form of illness, however, is also efficient in acquiring antimicrobial resistance (1, 8, 9) .
Clinical management of shigellosis
Three important aspects in the clinical management of shigellosis are: (i) prevention and management of dehydration, (ii) continued feeding, and (iii) institution of an effective antimicrobial agent.
The amount of body fluid loss in shigellosis is much less than in watery diarrhea (10) , and thus clinical dehydration is also uncommon. However, dehydration is a recognized risk factor for death from shigellosis (3) which can be prevented by administering home-based fluids, and can be efficiently treated using oral rehydration salt (ORS) solution.
For a number of reasons, the nutritional consequences of shigellosis is S43 much greater than the other, specific-etiologic diarrhea. First, shigellosis causes an intense inflammatory response in the large intestine (11) (12) (13) associated with severe anorexia and decreased food intake which may persist for weeks (14) . Second, there is incomplete absorption of nutrients (15) . Third, the acute phase response in shigellosis is associated with decreased protein synthesis (16) . Fourth, there is extensive loss of endogenous protein through ulcerated gut (17, 18) . Last is the metabolic cost of infection which is heightened in presence of fever-a feature present in the majority of patients with shigellosis (1) . Acting together, these factors contribute to deterioration in the nutritional status, and may cause overt malnutrition in a marginal malnourished child within a few days (1) . Moreover, prolonged fasting may lead to hypoglycemia, an important complication of shigellosis associated with a very high case-fatality rate (19) . The objectives for use of antimicrobial agents in the management of infectious diseases include (i) reduction in deaths, (ii) shortening the duration of illness, (iii) shortening the duration of excretion of pathogens and thereby reduce infection transmission, and (iv) prevention of complications,
Results of well-designed, controlled clinical trials clearly indicates the usefulness of effective agents in shortening the duration of illness (23). Since inflammation and gut ulceration in shigellosis begins in the rectosigmoid area and progresses proximally (24), it is conceivable that treatment with an effective antimicrobial will be useful in arresting the infection as well as its further progression, resulting in early resolution of fever, anorexia and abdominal pain. They, in turn, will decrease the metabolic demand, increase intake of food, increase absorption of nutrients, resolve the acute phase response and resumption of protein synthesis for growth, and lessen the loss of endogenous protein-all contributing to S44 decreased nutritional consequences of the disease.
Results of controlled clinical trails also indicate the role of effective antimicrobial therapy in significantly shortening the duration of fecal excretion of Shigella (23). This is an important objective since a very low infective dose of Shigella (25, 26), compared to other enteric pathogens, facilitates its person to person transmission which is also reflected by its higher secondary attack rates (1) .
Despite lack of evidence from case-control studies, there is a general consensus that antimicrobial therapy is also useful in reducing deaths from shigellosis. Higher case-fatality rates from shigellosis in the pre-antibiotic era, and also prior to institution of effective antimicrobial therapy during early epidemics, and reduced deaths observed during the later part of epidemics when an effective therapy is instituted, provides indirect evidence that antimicrobials are useful in reducing deaths (7, 27, 28) . However, better understanding of the disease process including its pathophysiology, and improvement in the fluid, electrolyte and dietary management must have had contributed to reduced deaths in the antibiotic era. On the other hand, ascertainment bias and change in the age-specific attack rates during an epidemic may explain reduced case-fatality later during an epidemic (23). However, the association of ineffective antimicrobial therapy and higher deaths and decline in the case-fatality associated with institution of effective antimicrobial therapy years after the beginning of epidemic, as observed in Africa (29), provides evidence that effective antimicrobial therapy can reduce deaths from shigellosis. Observation of deaths in association with ineffective therapy, but not with effective antimicrobial therapy provides further support (23).
It is reasonable to expect that early, effective antimicrobial therapy should reduce the frequency of complications, particularly those seen later during the course of the illness (23, 30). Early initiation of antimicrobial therapy has also been incriminated to be associated with increased risk for development of hemolytic uremic syndrome (HUS), an important complication of shigellosis, particularly when the infections are caused by S. dysenteriae type 1 (31). However, a causal relation is difficult to establish since S. dysen teriae type 1 infections are not only associated with more severe disease as well as development of HUS, but are also more likely to be treated early with an antimicrobial agent. On the other hand, the possibility of increased risk for development of HUS in association with ineffective antimicrobial therapy can't be ignored since such drugs may provide survival advantage to drug-resistant Shigeiia by eliminating susceptible colonic flora leading to more severe disease. In the treatment of infections due to enterohemorrhagic Escherichia coil which is also associated with HUS, although some studies have observed an association between antimicrobial therapy and development of HUS, others have failed to observe such as association (32-34).
Determinants of effective antimicrobials
Despite performing a large number of clinical trials evaluating a number of effective and ineffective antimicrobials belonging to various classes (23, 35, 36), the determinants of efficacy are yet to be fully elucidated.
Better efficacy and longer duration of usefulness of bactericidal drugs such as ampicillin, trimethoprim-sulfamethoxazole, pivmecillinam, ceftriaxone and newer quinolones compared to bacteriostatic agents such as sulfonamides and tetracyclines, and rapid emergence of resistance to the latter indicates the advantage of bactericidal over bacteriostatic drugs. Rapid emergence of resistance to chloramphenicol, a bactericidal agent, can be explained by the fact that the mechanisms of resistance, decrease permeability and efflux, is similar to that of tetracyclines. Similarly, rapid development of resistance to nalidixic acid, another bactericidal drug, can be explained by higher frequency of mutation, higher MIC relative to serum concentration, and higher protein binding with possible lower tissue concentration of this drug. Generally higher MIC of S. dysenteriae type 1 over others serotypes of Shigella is likely to be an important factor for its better efficiency in acquiring antimicrobial resistance (37). Thus, it may be summarized that to have potentials for being effective as well as delaying the emergence of resistant Shigella, an antimicrobial should, (i) have rapid bactericidal activity, preferably with post-antibiotic effect, (ii) achieve adequate serum and luminal, and more importantly tissue concentrations, (iii) have excellent potency with high serum to MIC ratio, and (iv) possess characteristics which do not favor emergence of plasmid-mediated resistance.
Antimicrobial
Resistance of Shigella
Like management of other infectious diseases, the concerns on antimicrobial therapy for shigellosis include cost of therapy and adverse effects, and most importantly, the emergence of resistant strains (42) (43) (44) . This problem has been noted, without any exception, with all antimicrobial agents introduced in the management of shigellosis. It is, however, the emergence and spread of multi-resistant Shigella which is now the major concern. The rapidity of emergence of antimicrobial resistance among Shigella has been observed to be influenced by the species and serotypes of Shigella as well as drug characteristics, among others.
Emergence of drug-resistant Shigella
Absorbable sulfonamides are more effective than the non-absorbable ones (8, 9, (20) (21) (22) , and the combination drug, trimethoprim-sulfamethoxazole, remained useful in the treatment of shigellosis for decades (23, [45] [46] [47] . Emergence of sulfonamide-resistant strains were reported from different geographic locations within a very short time of their introduction in the clinical practice; such strains have also been associated with epidemics among prisoners of the Korean war (8, 9, 48, 49) , and S. dyaenteriae type 1 has been the most efficient in acquiring resistance followed by S. flexneri and S. sonnei (8) .
Tetracyclines are among the early antimicrobial agents introduced in clinical practice, and they were effective against sulfonamide-resistant strains of Shigella (23, 49), however, emergence of tetracycline-resistant strains of S. dysenteriae type 1 and S. flexneri quickly followed; emergence of multiply-resistant strains and development of during-therapy emergence of resistance were also noted (8) .
Chlorarnphenicol has also been effective against sulfonamide-resistant strains of Shigella (8) . Resistance to chloramphenicol was first reported among epidemic strains of Shigella; one study in Israel not only observed a rapid increase in the resistance among Shigella but also cross-resistance to tetracycline and sulfonamides (8 A newer macrolide, azithromycin, has recently been found to be effective in the treatment of shigellosis in adults (38). It is likely that the drug will also be effctive in children, however, controlled clinical trails are required to prove its efficacy in the treatment of childhood shigellosis. There is a concern on the use of newer quinolones in children due to their arthropathogenic potentials (69), however, results of a recent study indicate that a 5-day course of ciprofloxacin suspension is safe for use in children with shigellosis (70) . As with treatment of urinary tract infections, nalidixic acid-resistant strains of Shigella emerged within a very short time of its introduction in the management of shigellosis, and S. dysenteriae type 1 is the most efficient in acquiring resistance to this drugs ; such strains have been observed to exhibit cross-resistance to a number of agents including tetracycline, chloramphenicol, ampicillin and trimethoprim-sulfamethoxazole (55, 63).
Mechanisms of action and resistance
The mechanism of resistance of antimicrobials are often related to their mechanisms of action. Antimicrobials may act by interfering with the metabolic pathways of susceptible organisms either by inhibiting enzyme systems or by competing with the substrates for synthesis of nutrients essential for growth or multiplication of bacteria. Trimethoprim and sulfonamides act by impairing two different steps of bacterial folic acid synthesis-the former inhibits the enzyme dihydrofolate reductase and the latter competes with para-aminobenzoic acid (PABA) for binding with the enzyme dihydropteroate. Sulfonamides are bacteriostatic, however, in combination with trimethoprim it produces a sequential and additive, bactericidal effect (71). Resistance to sulfonamides may be chromosomal or plasmid-mediated, and the mechanisms include increased production of PABA, reduced permeability, and more importantly decreased sensitivity of dihydropteroate to the drug (71). Resistance to trimethoprim is most often plasmid-mediated, and the mechanisms include increased synthesis of dihydrofolate, synthesis of the enzyme with less affinity for the drug, and reduced drug permeability (71). The quinolones act by blocking the activity of the bacterial DNA in a dose-dependent fashion (71), and they are active in the log phase as well as in the stationary phase of growth of bacterium. Resistance to quinolones is mediated by chromosomal mutation, and plasmid-mediated resistance has not been reported. The mechanism of resistance include changes in either of the subunits of the bacterial DNA gyrase (A or B), and nal B-encoded mutation resulting in reduced drug permeability where the bacterium also exhibits cross-resistance to other classes of antibiotics (85-87). The frequency of the in vitro resistance of Enterobacteriaceae to fluoroquinolones is lower than that of nalidixic acid (88), however, it remains to be seen what happens with increasing selection pressure; development of resistance to ciprofloxacin has been already been noted among strains of Campylobacter jejuni (89, 90).
Multidrug resistance
In this form of resistance, pathogens exhibiting resistance to one class of drug also exhibit resistance to unrelated classes of drugs. This phenomenon, first described in association with chemotherapy for cancer, is now a major problem in the management of infectious diseases including shigellosis, and is a consequence of efflux of drugs by primary efflux pump encoded by mdr 1 (42) . Emergence of multi-drug resistance Shigella was noted since the early days of antimicrobial therapy, and this problem is particularly noted during epidemics-during an epidemic in Israel, strains of S. flexneri were observed to be multiply-resistant to sulfonamides, tetracyclines and chloramphenicol (8) . In the seventies and eighties, multiply-resistant strains of S. sonnei and S. dysenteriae type 1 exhibiting resistance to subsequently introduced drugs such as ampicillin, trimethoprim-sulfamethoxazole and nalidixic acid have been associated with epidemics and foreign travel (52, 54, 58, 59, 61, (91) (92) (93) . In 1994, 24,000 people were killed during a major epidemic among the Rwandan refugees in Goma, Zaire which was caused by strains of S. dysenteriae type 1 multiply-resistant to ampicillin, trimethoprim-sulfamethoxazole and nalidixic acid (7) . Although less common, multidrug resistance has also been observed among endemic strains of S. flexneri in Navajo reservation in the USA (94), and in Thailand (95). In another endemic country, Bangladesh, all species of Shigella are currently multiply-resistant to ampicillin, trimethoprim-sulfamethoxazole and nalidixic acid, and some strains are additionally resistant to pivmecillinam (63 This is complicated by the facts that (i) an etiologic diagnosis of shigellosis can't be clinically made, and that (ii) conventional laboratory tests will not only be unable to identify all cases of Shigella infections but will also be expensive as well as time-consuming and thus difficult to implement, particularly in the developing countries where the magnitude of the problem is the greatest. Infancy, malnutrition, presence of dehydration and acidosis, nonbreast feeding, and presence of complications such as hypoglycemia, hyponatrernia, intestinal obstruction and septicemia are recognized risk factors for death (96, 97). Thus, such groups of population will benefit most from an effective antimicrobial therapy, and should be routinely treated. Disease severity is known to be more in malnourished children, and also when the infections are caused by S. dysenteriae type 1, although some studies failed to observe any association between case-fatality among hospitalized children and species of Shigella (3, 4) . A strong argument for routine use of antimicrobial therapy for all clinically suspected cases of shigellosis is that deaths are not confined only to high-risk population and that reducing disease severity and the duration of illness are also important objectives of antimicrobial therapy for shigellosis. The disease severity and deaths are both higher in epidemic disease, and thus all cases during an epidemic should be treated adequately with an effective agent. Since epidemics are often caused by multidrug resistant Shigella, it will be important to determine antimicrobial susceptibility of the strain of Shigella causing the epidemic within shortest possible time in order to define appropriate antimicrobial therapy. The case-fatality from shigellosis is higher among those with complications such as hypoglycemia, septicemia, toxic megacolon and hyponatremia. Thus, limiting use of antimicrobials for those with complications could be one strategy. However, early, effective antimicrobial therapy is considered to prevent many of the potential complications of shigellosis and deaths, and deferring antimicrobial therapy until the time of development of complications will not S53 be a practical approach.
c. Use effective antimicrobials in rotation
Selective pressure is an important determinant of emergence of resistant strains, and reduced use of chloramphenicol has been reported to reduce the prevalence of resistant strains of Salmonella typhi (63) . However, antimicrobials which are useful in the treatment of shigellosis may have other indications, and thus their withdrawal from a community will not be possible.
Switching from one effeective drug to another before emergence of resistant strains could be an option. However, because of diverse indications for use of the antimicrobial agents, organizational difficulties, and the need for continuous monitoring of antimicrobial susceptibility which is known to vary widely from one community to another, it will be difficult to implement this policy, particularly in the developing countries where the problem is the greatest and the use of antimicrobials is not controlled (23). Most importantly, optimal time to switch can not be reasonably determined due to inability to predict emergence of resistant strains.
2.3
Appropriate use of effective antimicrobials
Administration of antimicrobials without indication, or their use in inadequate dose or duration, and decreased patient compliance are among the factors known to facilitate emergence of resistant strains. This is a global problem, however, the magnitude is more in the developing countries where promotion of appropriate use of antimicrobial agents will be a formidable task (63 Selection of an ideal agent will require a good understanding of the attributes of drugs which will make the organisms less likely develop resistance to them. Review of the past experience on antimicrobial therapy for shigellosis may be useful in this regard. An ideal antimicrobial with potentials for being most effective and at the same time likely to delay the emergence of resistant Shigella, in addition to being safe and less expensive, should (i) be rapidly bactericidal, preferably with postantibiotic effect, (ii) achieve adequate serum and luminal, and more importantly, tissue concentrations, and (iii) have excellent potency with high serum to MIC ratio. Spread of resistant is facilitated when the mechanism of resistance is encoded on plasmids, hence, use of drugs to which resistance is not plasmid-mediated could be another way of delaying emergence of resistant strains. 
Other options

